GW Pharmaceuticals plc has announced that it has received commercialisation approval for its prescription medicine Sativex® in Italy. A full marketing authorization has been granted by the authorities in Italy for the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications....... Read More - http://www.ms-uk.org/index.cfm/sativex

Cannabis-based oral spray approved for use in Ireland

The Irish medical board has approved a cannabis-based spray, which can ease symptoms and significantly improve the quality of life of people suffering from illnesses like multiple sclerosis....... Read More - http://www.ms-uk.org/index.cfm/MSnews

There is no strong evidence to back the use of cannabis extract in the treatment of Multiple Sclerosis (MS), concludes a review of the available evidence on the first licensed preparation, published in the December issue of Drug and Therapeutics Bulletin (DTB).

Sativex, in the form of a mouth spray, contains the principal extracts—dronabinol and cannabidiol—found in the leaf and flower of the cannabis plant. It is the first cannabinoid preparation to be licensed ...

HI Friends
http://www.southernhighlandnews.com.au/ ... harmacies/
THIS IS IN TODAYS SYDNEY MORNING HERALD PAPER. SOON THE TRIAL IN AUSTRALIA PLEASE READ THE WEB FORMOR INFORMATIONS
regards
seeva

Almirall S.A. announced that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month's treatment with Sativex®(THC:CBD) oromucosal spray reduces moderate to severe multiple sclerosis spasticity (MSS) by 20% or more in 4 out of 10 patients previously unresponsive to conventional therapies. After three months, the improvement observed was 30% or more. Overall, 55% of the initial patients were eligible ...

An extract from the plant Cannabis sativa (trade name Sativex®) was approved in May 2011 for patients suffering from moderate to severe spastic paralysis and muscle spasms due to multiple sclerosis (MS). In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether the new drug, which is used as a mouth spray, ...

Sativex long-term use: an open-label trial in patients with spasticity due to MS



Summary: This new study from a research group in Scotland assesses the long term safety profile of regular Sativex use for spasticity in MS.

The report, which follows-up 146 patients using treatment for a mean duration of 334 days, administering a mean of 7.3 actuations per day, found that 36% withdrew in the first year, either due to adverse events of ...

Sativex® mutual recognition procedure closes with recommendation for approval in ten european countries




GW Pharmaceuticals plc and Almirall S.A. today announce the successful completion of the European Mutual Recognition Procedure (MRP) for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS).

Following previous positive regulatory submissions in the UK, Spain, Germany, Italy, Denmark Sweden, Austria, Czech Republic, a MRP application was made to expand the availability of Sativex® to ten ...

Medicinal cannabis is now available as a prescription medicine in Sweden after the Medical Products Agency (Läkemedelsverket) approved a cannabis-based mouth spray for the treatment of multiple sclerosis (MS).

"This is great news for those who can't get any relief from the most common drugs," said Jan Hillert, an MS researcher at Karolinska Institutet, to the Dagens Nyheter daily.

The agency has said that it plans to closely monitor the prescription of the new ...